Biotech News
News | Bavarian Nordic
December 23, 2022 | Company Announcements
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
December 08, 2022 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
November 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
November 17, 2022 | Company Announcements
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox Vaccines
November 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2022
October 17, 2022 | Company Announcements
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
September 20, 2022 | Company Announcements
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
September 20, 2022 | Company Announcements
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada
September 07, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
September 07, 2022 | Company Announcements
Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA)
September 02, 2022 | Company Announcements
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
August 24, 2022 | Company Announcements
Bavarian Nordic Announces First Half 2022 Results
August 23, 2022 | Company Announcements
Elizabeth McKee Anderson Resigns from the Board of Directors of Bavarian Nordic
August 03, 2022 | Company Announcements
Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023
July 22, 2022 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox
July 19, 2022 | Company Announcements
Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023
July 18, 2022 | Company Announcements
Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox Outbreak
July 15, 2022 | Company Announcements
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic
July 01, 2022 | Company Announcements
U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic
June 14, 2022 | Company Announcements
Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak
June 10, 2022 | Company Announcements
Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government
June 07, 2022 | Company Announcements
Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of Canada
May 30, 2022 | Company Announcements
Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox Outbreak
May 25, 2022 | Company Announcements
Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox Outbreak
May 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise